Fujie Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/663560/publications.pdf

Version: 2024-02-01

120	4,071	29 h-index	58
papers	citations		g-index
125	125	125	6340
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clinical Infectious Diseases, 2020, 71, 793-798.	2.9	578
2	Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infectious Diseases, The, 2011, 11, 516-524.	4.6	234
3	Five-Year Outcomes of the China National Free Antiretroviral Treatment Program. Annals of Internal Medicine, 2009, 151, 241.	2.0	221
4	SARS-CoV-2–Positive Sputum and Feces After Conversion of Pharyngeal Samples in Patients With COVID-19. Annals of Internal Medicine, 2020, 172, 832-834.	2.0	190
5	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity, 2021, 54, 1611-1621.e5.	6.6	190
6	The Chinese free antiretroviral treatment program: challenges and responses. Aids, 2007, 21, S143-S148.	1.0	159
7	A multi-omics investigation of the composition and function of extracellular vesicles along the temporal trajectory of COVID-19. Nature Metabolism, 2021, 3, 909-922.	5.1	132
8	Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003–11): a national observational cohort study. Lancet, The, 2013, 382, 1195-1203.	6.3	127
9	Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infectious Diseases, The, 2019, 19, 253-264.	4.6	114
10	HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–12: a retrospective observational cohort study. Lancet Infectious Diseases, The, 2014, 14, 1065-1072.	4.6	109
11	The Effect of Highly Active Antiretroviral Therapy on Mortality among HIVâ€Infected Former Plasma Donors in China. Clinical Infectious Diseases, 2008, 47, 825-833.	2.9	91
12	CD14highCD16+ Rather Than CD14lowCD16+ Monocytes Correlate With Disease Progression in Chronic HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 553-559.	0.9	79
13	Predictors of Virologic Failure in HIVâ€1–Infected Adults Receiving Firstâ€Line Antiretroviral Therapy in 8 Provinces in China. Clinical Infectious Diseases, 2010, 50, 264-271.	2.9	74
14	Clinical and epidemiological features of COVID-19 family clusters in Beijing, China. Journal of Infection, 2020, 81, e26-e30.	1.7	71
15	Cohort Profile: The Chinese national free antiretroviral treatment cohort. International Journal of Epidemiology, 2010, 39, 973-979.	0.9	67
16	HIV-Infected Former Plasma Donors in Rural Central China: From Infection to Survival Outcomes, 1985–2008. PLoS ONE, 2010, 5, e13737.	1.1	65
17	A Preliminary Randomized Controlled Trial of a Nurse-Delivered Medication Adherence Intervention Among HIV-Positive Outpatients Initiating Antiretroviral Therapy in Beijing, China. AIDS and Behavior, 2011, 15, 919-929.	1.4	55
18	PrEP uptake preferences among men who have sex with men in China: results from a National Internet Survey. Journal of the International AIDS Society, 2019, 22, e25242.	1,2	50

#	Article	IF	CITATIONS
19	A fatal yellow fever virus infection in China: description and lessons. Emerging Microbes and Infections, $2016, 5, 1-8$.	3.0	49
20	Scale-up of national antiretroviral therapy programs: progress and challenges in the Asia Pacific region. Aids, 2010, 24, S62-S71.	1.0	46
21	Initiation of the National Free Antiretroviral Therapy Program in Rural China. , 0, , 96-124.		46
22	Late Presentation into Care of HIV Disease and Its Associated Factors in Asia: Results of TAHOD. AIDS Research and Human Retroviruses, 2016, 32, 255-261.	0.5	42
23	The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages. Emerging Microbes and Infections, 2017, 6, 1-7.	3.0	40
24	Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival. PLoS ONE, 2016, 11, e0150512.	1.1	40
25	Two-step fitness selection for intra-host variations in SARS-CoV-2. Cell Reports, 2022, 38, 110205.	2.9	38
26	Chinese Pediatric Highly Active Antiretroviral Therapy Observational Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 594-598.	0.9	37
27	Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-09. International Journal of Epidemiology, 2010, 39, ii56-ii64.	0.9	35
28	Hepatitis B and Hepatitis C Seroprevalence in Children Receiving Antiretroviral Therapy for Human Immunodeficiency Virus-1 Infection in China, 2005-2009. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 191-196.	0.9	33
29	Decreasing Excess Mortality of HIV-Infected Patients Initiating Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, e150-e157.	0.9	33
30	Gender Difference in 2-Year Mortality and Immunological Response to ART in an HIV-Infected Chinese Population, 2006–2008. PLoS ONE, 2011, 6, e22707.	1.1	33
31	Mortality and Treatment Outcomes of China's National Pediatric Antiretroviral Therapy Program. Clinical Infectious Diseases, 2013, 56, 735-744.	2.9	32
32	Implementation of "Treatâ€all―at adult <scp>HIV</scp> care and treatment sites in the Global le <scp>DEA</scp> Consortium: results from the Site Assessment Survey. Journal of the International AIDS Society, 2019, 22, e25331.	1.2	32
33	Attrition among Human Immunodeficiency Virus (HIV)- Infected Patients Initiating Antiretroviral Therapy in China, 2003–2010. PLoS ONE, 2012, 7, e39414.	1.1	30
34	Interventions to improve the HIV continuum of care in China. Current HIV/AIDS Reports, 2019, 16, 448-457.	1.1	29
35	Therapeutic drug monitoring in highly active antiretroviral therapy. Expert Opinion on Drug Safety, 2010, 9, 743-758.	1.0	28
36	HIV testing and care systems focused on sexually transmitted HIV in China. Sexually Transmitted Infections, 2012, 88, 116-119.	0.8	28

#	Article	IF	CITATIONS
37	Methadone maintenance treatment and mortality in HIV-positive people who inject opioids in China. Bulletin of the World Health Organization, 2013, 91, 93-101.	1.5	28
38	"You Must Take the Medications for You and for Me†Family Caregivers Promoting HIV Medication Adherence in China. AIDS Patient Care and STDs, 2011, 25, 735-741.	1.1	27
39	Genomic surveillance of COVID-19 cases in Beijing. Nature Communications, 2020, 11, 5503.	5.8	26
40	Excessive conversion and impaired thymic output contribute to disturbed regulatory T-cell homeostasis in AIDS patients with low CD4 cell counts. Aids, 2013, 27, 1059-1069.	1.0	25
41	Diabetes mellitus burden among people living with ⟨scp⟩HIV⟨/scp⟩ from the Asiaâ€Pacific region. Journal of the International AIDS Society, 2019, 22, e25236.	1.2	25
42	Phylogenomic analysis unravels evolution of yellow fever virus within hosts. PLoS Neglected Tropical Diseases, 2018, 12, e0006738.	1.3	24
43	COVID-19 reinfection in the presence of neutralizing antibodies. National Science Review, 2021, 8, nwab006.	4.6	24
44	Immune restoration in HIV-1-infected patients after 12 years of antiretroviral therapy: a real-world observational study. Emerging Microbes and Infections, 2020, 9, 2550-2561.	3.0	23
45	Progress of the National Pediatric Free Antiretroviral Therapy program in China. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 1182-1188.	0.6	22
46	Drug Resistance Profiles Among HIV-1–Infected Children Experiencing Delayed Switch and 12-Month Efficacy After Using Second-Line Antiretroviral Therapy: An Observational Cohort Study in Rural China. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 47-53.	0.9	22
47	Transmitted HIV drug resistance among individuals with newly diagnosed HIV infection: a multicenter observational study. Aids, 2020, 34, 609-619.	1.0	21
48	Prevalence and mortality of cancer among HIV-infected inpatients in Beijing, China. BMC Infectious Diseases, 2016, 16, 82.	1.3	20
49	Gender Differences in Outcomes of Antiretroviral Treatment Among HIV-Infected Patients in China: A Retrospective Cohort Study, 2010–2015. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 281-288.	0.9	20
50	PrEP in China: choices are ahead. Lancet HIV,the, 2020, 7, e155-e157.	2.1	20
51	Trends in First-Line Antiretroviral Therapy in Asia: Results from the TREAT Asia HIV Observational Database. PLoS ONE, 2014, 9, e106525.	1.1	18
52	The Diagnosis and Treatment of HIV-Infected Children in China. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 429-434.	0.9	17
53	Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific. PLoS ONE, 2016, 11, e0161562.	1.1	17
54	Incidence and associated factors of pulmonary tuberculosis in HIV-infected children after highly active antiretroviral therapy (HAART) in China: a retrospective study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 1127-1135.	0.6	16

#	Article	IF	CITATIONS
55	Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 239-243.	0.9	16
56	The Chinese Life-Steps Program: A Cultural Adaptation of a Cognitive-Behavioral Intervention to Enhance HIV Medication Adherence. Cognitive and Behavioral Practice, 2013, 20, 202-212.	0.9	13
57	The Prevalence of HIV-1 Drug Resistance among Antiretroviral Treatment NaÃ-ve Individuals in Mainland China: A Meta-Analysis. PLoS ONE, 2014, 9, e110652.	1.1	13
58	Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China. Bulletin of the World Health Organization, 2015, 93, 152-160.	1.5	13
59	Impact of Gender on Long-Term Treatment Outcomes of Highly Active Antiretroviral Therapy (HAART) in the TREAT Asia HIV Observational Database. AIDS Patient Care and STDs, 2015, 29, 229-231.	1.1	13
60	Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. Pharmacotherapy, 2017, 37, 1073-1080.	1.2	13
61	The influence of ageâ€associated comorbidities on responses to combination antiretroviral therapy in older people living with <scp>HIV</scp> . Journal of the International AIDS Society, 2019, 22, e25228.	1.2	13
62	Clinical Characteristics and Risk Factors of Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients in Beijing, China: A Retrospective Study. Medical Science Monitor, 2020, 26, e925974.	0.5	13
63	Some patient-related factors associated with late access to ART in China's free ART program. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 1226-1235.	0.6	12
64	Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes. Open Forum Infectious Diseases, 2016, 3, ofv158.	0.4	12
65	Effects of unplanned treatment interruptions on <scp>HIV</scp> treatment failure – results from <scp>TAHOD</scp> . Tropical Medicine and International Health, 2016, 21, 662-674.	1.0	11
66	Mortality and virological failure among HIV-infected people who inject drugs on antiretroviral treatment in China: An observational cohort study. Drug and Alcohol Dependence, 2017, 170, 189-197.	1.6	11
67	Monitoring HIV Drug Resistance Using Early Warning Indicators in China: Results From a Pilot Survey Conducted in 2008. Clinical Infectious Diseases, 2012, 54, S300-S302.	2.9	10
68	Predictors of accessing antiretroviral therapy among <scp>HIV</scp> â€positive drug users in <scp>C</scp> hina's <scp>N</scp> ational <scp>M</scp> ethadone <scp>M</scp> aintenance <scp>T</scp> reatment <scp>P</scp> rogramme. Addiction, 2015, 110, 40-50.	1.7	10
69	HIV-1 low-level viremia affects T cell activation rather than T cell development in school-age children, adolescents, and young adults during antiretroviral therapy. International Journal of Infectious Diseases, 2020, 91, 210-217.	1.5	10
70	Persistent Low-Level Viremia is an Independent Risk Factor for Virologic Failure: A Retrospective Cohort Study in China. Infection and Drug Resistance, 2021, Volume 14, 4529-4537.	1.1	10
71	Risk factors associated with preterm delivery and low delivery weight among <scp>HIV</scp> â€exposed neonates in China. International Journal of Gynecology and Obstetrics, 2018, 142, 300-307.	1.0	9
72	Early suboptimal ART adherence was associated with missed clinical visits in HIV-infected patients in Asia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1560-1566.	0.6	9

#	Article	IF	CITATIONS
73	First Case of Coronavirus Disease 2019 in Childhood Leukemia in China. Pediatric Infectious Disease Journal, 2020, 39, e142-e145.	1.1	9
74	Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China. Pharmacogenomics and Personalized Medicine, 2022, Volume 15, 195-203.	0.4	9
75	Knowledge and perceptions of sexual and reproductive health and HIV among perinatally HIV-infected adolescents in rural China. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 1137-1142.	0.6	8
76	Changes in renal function with longâ€term exposure to antiretroviral therapy in HIVâ€infected adults in Asia. Pharmacoepidemiology and Drug Safety, 2018, 27, 1209-1216.	0.9	8
77	Early and Late Virologic Failure After Virologic Suppression in HIV-Infected Asian Children and Adolescents. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 308-315.	0.9	8
78	Specific dynamic variations in the peripheral blood lymphocyte subsets in COVID-19 and severe influenza A patients: a retrospective observational study. BMC Infectious Diseases, 2020, 20, 910.	1.3	8
79	Growth of HIV-Infected Children in the Early Stage of Antiretroviral Treatment: A Retrospective Cohort Study in China. AIDS Patient Care and STDs, 2016, 30, 365-370.	1.1	7
80	Mitochondrial DNA mutations accumulated in HIV-1-infected children who have an excellent virological response when exposed to long-term antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2018, 73, 3114-3121.	1.3	7
81	Distinct durability of IgM/IgG antibody responses in COVID-19 patients with differing severity. Science China Life Sciences, 2022, 65, 223-226.	2.3	7
82	Longitudinal analysis of newâ€onset nonâ€AIDSâ€defining diseases among people living with HIV: A realâ€world observational study. HIV Medicine, 2022, 23, 32-41.	1.0	7
83	Unsafe Sex and STI Prevalence Among HIV-Infected Adults in Guangzhou, China: Opportunities to Deamplify Sexual HIV Transmission. AIDS and Behavior, 2013, 17, 1137-1143.	1.4	6
84	Progress and challenges in China's free ART programme. Lancet HIV, the, 2019, 6, e8-e9.	2.1	6
85	Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV. Journal of the International AIDS Society, 2019, 22, e25264.	1.2	6
86	The Yield and Consistency of the Detection of SARS-CoV-2 in Multiple Respiratory Specimens. Open Forum Infectious Diseases, 2020, 7, ofaa379.	0.4	6
87	Specific Redistribution of Severe Acute Respiratory Syndrome Coronavirus 2 Variants in the Respiratory System and Intestinal Tract. Clinical Infectious Diseases, 2021, 73, e2814-e2817.	2.9	6
88	A retrospective study of distribution of HIV associated malignancies among inpatients from 2007 to 2020 in China. Scientific Reports, 2021, 11, 24353.	1.6	6
89	Comparing Outcomes of HIV-Infected Chinese Adults on Antiretroviral Therapy by CD4 Count at Treatment Initiation: A Nationwide Retrospective Observational Cohort Study, 2012–2014. AIDS Patient Care and STDs, 2017, 31, 413-420.	1.1	5
90	Two types of poor immunological responder showing distinct responses to long-term HAART. International Journal of Infectious Diseases, 2019, 86, 178-187.	1.5	5

#	Article	IF	Citations
91	Validation of the D:A:D Chronic Kidney Disease Risk Score Model Among People Living With HIV in the Asia-Pacific. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 489-497.	0.9	5
92	Drug resistance profiles and influencing factors among HIV-infected children and adolescents receiving long-term ART: a multicentre observational study in China. Journal of Antimicrobial Chemotherapy, 2022, 77, 727-734.	1.3	5
93	Recent key advances in human immunodeficiency virus medicine and implications for China. AIDS Research and Therapy, 2010, 7, 12.	0.7	4
94	The Clinical Significance of CD4 Counts in Asian and Caucasian HIV-Infected Populations: Results from TAHOD and AHOD. Journal of the International Association of Providers of AIDS Care, 2011, 10, 160-170.	1.2	4
95	Expansion of HIV care and treatment in Yunnan Province, China: Treatment outcomes with scale up of combination antiretroviral therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 633-641.	0.6	4
96	Brief Report: Malignancies in Adults Living With HIV in Asia. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 301-307.	0.9	4
97	Transmitted and Acquired HIV-1 Drug Resistance from a Family: A Case Study. Infection and Drug Resistance, 2020, Volume 13, 3763-3770.	1.1	4
98	Weight changes, metabolic syndrome and allâ€cause mortality among Asian adults living with HIV. HIV Medicine, 2022, 23, 274-286.	1.0	4
99	Factors associated with survival among adults with HIV-associated TB in Guangxi, China: a retrospective cohort study. Future Virology, 2012, 7, 933-942.	0.9	3
100	Identification of a Novel HIV Type 1 CRF01_AE/Bâ \in 2/C Recombinant Isolate in Sichuan, China. AIDS Research and Human Retroviruses, 2017, 33, 621-628.	0.5	3
101	The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the <scp>TREAT</scp> Asia <scp>HIV</scp> Observational Database (<scp>TAHOD</scp>). Journal of the International AIDS Society, 2017, 20, e25016.	1.2	3
102	Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance. Journal of Infectious Diseases, 2017, 216, S816-S819.	1.9	3
103	The stage-specific impairment of granulopoiesis in people living with HIV/AIDS (PLWHA) with neutropenia. Journal of Leukocyte Biology, 2020, 107, 635-647.	1.5	3
104	HIV treatment outcomes among people who acquired HIV via injecting drug use in the Asiaâ€Pacific region: a longitudinal cohort study. Journal of the International AIDS Society, 2021, 24, e25736.	1.2	3
105	Early and consecutive RT-PCR tests with both oropharyngeal swabs and sputum could improve testing yield for patients with COVID-19: An observation cohort study in China. International Journal of Infectious Diseases, 2021, 107, 242-246.	1.5	3
106	Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, $2014\hat{a}\in^{\circ}18$. Journal of Antimicrobial Chemotherapy, 2022, , .	1.3	3
107	Near Full-Length Genome Identification of a Novel HIV-1 Unique (B/C) Recombinant Isolate in Sichuan, China. AIDS Research and Human Retroviruses, 2016, 32, 1229-1233.	0.5	2
108	Phylogenomic tracing of asymptomatic transmission in a COVID-19 outbreak. Innovation(China), 2021, 2, 100099.	5.2	2

#	Article	IF	CITATIONS
109	Strategy to Achieve Full Coverage in theÂNational Free Antiretroviral Therapy Program. , 2020, , 271-289.		2
110	Prevalence and Risk Factors of Low Bone Mineral Density in HIV/AIDS Patients: a Chinese Cross-sectional Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, Publish Ahead of Print, .	0.9	2
111	Seroprevalence of HBV and HCV among HIV-infected adults in China according to route of HIV infection: high rate of HBV and HCV exposure. Future Virology, 2012, 7, 1015-1020.	0.9	1
112	Partial recovery of disturbed V-J pairing profiles of T-cell receptor in people living with HIV receiving long-term antiretroviral therapy. Science China Life Sciences, 2021, 64, 152-161.	2.3	1
113	Reply to Aquino-Jarquin. Clinical Infectious Diseases, 2021, 72, 1490-1491.	2.9	1
114	Treatment modification after second-line failure among people living with HIV in the Asia-Pacific. Antiviral Therapy, 2021, 25, 377-387.	0.6	1
115	Patterns and prognosis of holding regimens for people living with HIV in Asian countries. PLoS ONE, 2022, 17, e0264157.	1.1	1
116	1569The effects of frequency of CD4 monitoring on clinical endpoints in clinically stable HIV-infected patients with viral suppression. Open Forum Infectious Diseases, 2014, 1, S418-S418.	0.4	0
117	Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings. AIDS Research and Therapy, 2017, 14, 27.	0.7	0
118	Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Related Mortality. Open Forum Infectious Diseases, 2017, 4, S59-S59.	0.4	0
119	The Safety of Substitution of Antiretroviral Regimen in Non-Clinical Trial Settings in Asian Countries. Open Forum Infectious Diseases, 2017, 4, S432-S432.	0.4	0
120	Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Associated Mortality. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 436-443.	0.9	0